ReCode Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully raised $15 million in a recent funding round, underscoring the momentum behind its innovative approach to mRNA and gene correction therapeutics. With an advanced selective organ targeting (SORT) lipid nanoparticle (LNP) platform, ReCode is at the forefront of genetic medicine, providing a breakthrough technology that allows for precise delivery of therapeutics to target organs and cells beyond the liver鈥攁 significant leap forward in the field. This latest infusion of capital will be instrumental in evolving the company鈥檚 next-generation therapies, enabling accelerated development of treatments that can address unmet medical needs across a range of diseases. Additionally, the funding will bolster research and development efforts, particularly in the areas of rare diseases and conditions where traditional delivery mechanisms have fallen short. ReCode Therapeutics is committed to transforming the landscape of genetic medicine, and this funding not only validates its potential but also positions the company to expand its pipeline and amplify its impact on patient outcomes. As ReCode moves toward clinical trials and broader applications of its SORT platform, the support from investors is a testament to the trust placed in their vision of harnessing the power of mRNA and gene correction technology鈥攁n essential step in the journey to unlock new therapeutic possibilities.
Revolutionizing Genetic Medicines: ReCode Therapeutics Secures $15 Million in Funding for Cutting-Edge mRNA and Gene Correction Therapeutics
Recently funded 路 $15.0MGenetic Medicine
Get the full ReCode Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
